Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/SCN8A Encephalopathy

Neurological & Neuromuscular

SCN8A Encephalopathy Clinical Trials and Treatments

Also called SCN8A-DEE, SCN8A-Related Epilepsy, SCN8A-Related Epilepsy With Encephalopathy, SCN8A Developmental and Epileptic Encephalopathy, Nav1.6 Channelopathy, SCN8A Epilepsy, Early Infantile Epileptic Encephalopathy 13

SCN8A carries the instructions for Nav1.6, one of the sodium channels that let electrical signals start and travel in nerve cells.

In plain words, SCN8A encephalopathy is a rare genetic condition caused by a change in a gene that helps brain cells send signals. Seizures usually start in the first months of life and are often hard to control, along with slower development and movement problems.

Get an email when new SCN8A Encephalopathy trials open or the FDA decides. Get alerts

SCN8A Encephalopathy

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review1

Relutrigine, Dec 27, 2026

FDA-approved medicines0

No medicine's current FDA label names SCN8A Encephalopathy yet.

SCN8A Encephalopathy has no FDA-approved medicines, 0 open or active clinical trials (0 recruiting), and a pending FDA decision on Relutrigine, due Dec 27, 2026.

Labels checked October 21, 2026.Download the data

Latest for SCN8A Encephalopathy

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about SCN8A Encephalopathy

Most of the changes that cause SCN8A encephalopathy make the channel stay open longer than it should, so sodium keeps flowing in and the cell keeps firing. The brain becomes prone to seizures from infancy, and the repeated seizures, together with the faulty channel itself, interfere with development. A smaller group of changes do the opposite and weaken the channel; those children more often have developmental delay and autism features, and only 50-70% of them have epilepsy.

Keep reading about SCN8A Encephalopathy

In the severe form, called SCN8A developmental and epileptic encephalopathy, about half of children have severe intellectual disability and most speak few or no words. Movement disorders are common: low tone at first, then dystonia, chorea, ataxia or spasticity. Swallowing problems can lead to aspiration pneumonia, and breathing failure can occur. In one study of 190 people, 5.3% had died, with sudden unexpected death in epilepsy confirmed in 1.6%.

Because the overactive channel is the problem, the sodium channel blockers used in ordinary epilepsy, including phenytoin, carbamazepine, oxcarbazepine, lacosamide and lamotrigine, are often helpful, and some children respond to higher doses of phenytoin than are usual. Those same drugs can worsen seizures in the minority whose channel is underactive, and some families report that levetiracetam makes seizures worse. The ketogenic diet, vagus nerve stimulation and steroids are used when medicines fail.

What are the symptoms of SCN8A Encephalopathy?

These are common symptoms of SCN8A Encephalopathy, and how strong they are varies from person to person.

  • Seizures starting between birth and about 2 years of age, at a median age of 3 months
  • Several seizure types in the same child, including spasms, staring spells, jerks and convulsions
  • Seizures that resist medicines, sometimes hundreds a day
  • Developmental delay or regression, with few or no words in the severe form
  • Low muscle tone early, then stiffness or involuntary movements over time
  • Feeding and swallowing difficulty, and in the severe form, aspiration pneumonia or breathing problems

Who gets SCN8A Encephalopathy?

Nearly all cases are new (de novo) changes in the child, so parents are unaffected and there is no family history. The disease is almost entirely one of children; most people diagnosed are under 20, and the oldest known patient was 47. The most common pattern, SCN8A-DEE, begins with seizures at a median age of 3 months. Milder patterns exist: some children have seizures that start later, and some have developmental delay or autism without epilepsy, usually when the gene change reduces channel activity rather than increasing it.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new SCN8A Encephalopathy medicines are in trials?

Investigational medicines Trial Friend tracks for SCN8A Encephalopathy, with trial results, safety findings and where each one stands.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for SCN8A Encephalopathy

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted SCN8A Encephalopathy resources

Reputable organizations and medical references for learning more about SCN8A Encephalopathy, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for SCN8A Encephalopathy

This SCN8A Encephalopathy clinical trial finder lists studies as they become available, with eligibility criteria in plain English. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Relutrigine, due December 27, 2026. All upcoming decisions

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

No active clinical trials yet

SCN8A Encephalopathy is a classified rare disease, but clinical trial activity for it is limited. That's part of why we track it. When a trial opens, Trial Friend will have it.

Get an email the moment a SCN8A Encephalopathy trial is registered on ClinicalTrials.gov.

SCN8A Encephalopathy patient communities

Facebook groups, Reddit communities and YouTube channels where SCN8A Encephalopathy patients, caregivers and advocacy groups talk.

SCN8A Encephalopathy news and guides

Trial Friend articles about SCN8A Encephalopathy, newest first

Companies developing SCN8A Encephalopathy treatments

Drugmakers that list SCN8A Encephalopathy in their rare disease portfolio, 2 in all.

Questions people ask about SCN8A Encephalopathy